RxDoctor Payments Data

Seema Sood, MD

Internal Medicine · Las Vegas, NVNPI 1386669117

Payments from drug & device makers

$1,584in general payments, 2019–2025

Across 70 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$274
  • Pfizer$226
  • Abbott$210
  • Amarin Pharma, Inc.$164
  • AbbVie$162
  • Johnson & Johnson$113
  • plus $436 from 14 others

What the payments were for

  • Food & beverage$1,55498%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,584 in reported general payments places this provider in the 80th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$90,485
Medicare patients
95
Services billed
703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate30$23,456
FarxigaDapagliflozin Propanediol21$16,283
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,243
ProtonixPantoprazole Sodium12$5,129
SynthroidLevothyroxine Sodium22$1,450
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen25$1,448
Ezetimibe44$1,267
Levothyroxine Sodium123$1,171
Atorvastatin Calcium129$969
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen33$852
Pravastatin Sodium67$808
Potassium Chloride26$714
Alendronate Sodium46$701
Metoprolol Succinate36$541
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide35$515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$111$16,28321 claims
GSKTrelegy Ellipta$24$9,24312 claims
PfizerProtonix$226$5,12912 claims
AbbVieSynthroid$162$1,45022 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$14$20318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →